<DOC>
	<DOC>NCT02070991</DOC>
	<brief_summary>Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.</brief_summary>
	<brief_title>Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction, Left</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1. Males and Females &gt;=18 years of age 2. Subjects with combined preand postcapillary Pulmonary Hypertension (CpcPH) due to left ventricular dysfunction (subset of WHO groups 2.1 and 2.2) 3. Optimized diuretic therapy 1. Types of Pulmonary Hypertension other than WHO groups 2.1 and 2.2 (Nice classification) 2. Administration of PAHspecific therapy (i.e., Endothelin receptor antagonists (ERAs), Prostanoids, Phosphodiesterase 5 (PDE5) inhibitors, guanylate cyclase stimulators)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pre- and post-capillary pulmonary hypertension</keyword>
	<keyword>CpcPH</keyword>
</DOC>